The project is the first botanical extraction business in South Africa addressing the issues of unprofitable tea estates by making them viable through the harvesting of fresh green tea leaf for the sole purpose of extracting a bioavailable green tea gallate catechin extract.

"The dynamic growth of this industry using formulated green tea extracts as alternative medicine or as a synergistic combination therapy with pre-existing antiviral or antibiotics depends on a method of delivery that ensures its stability and greater bioavailability. Green tea and green tea extracts are one of the most researched agents in the natural botanical sector, with over 20 years of investigations supporting five hundred research studies published identifying markets and final products that deliver benefits in weight loss, anti-aging, treating diabetes 1 & 2, blood cholesterol lowering, treating high blood pressure, and relieving symptoms of certain cancers and malaria. The market for green tea is in a high growth stage with increasing annual volume growth rates between 13-14 percent. (Frost & Sullivan Research, 2011).

With all of the above in mind, a conservative, quick "back of the envelope calculation" gives Plandaí an income of $27,000,000 in 2012-2013, accelerating within 5 years of inception to $90,000,000 +.

Once we've pounded the streets and the dust has settled, Plandaí's market valuation will be one that truly reflects its ability to deliver products that far exceed ANYTHING that is available, making us, to date, the most undervalued company in our space.

Plandaí Biotechnology is the culmination of over ten years of research in the field of plant extracts. Its principle holdings consist of land, farms and infrastructure, totaling more than 7500 acres, in the province of Mpumalanga, South Africa.